Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

ETON 11.06.2024

SERA-AI Powered Highlights
Drug:ALKINDI-001 ALKINDI SPRINKLE®
Drug:PKU-002 PKU GOLIKE®
Drug:CARG-003 Carglumic Acid
Drug:BETA-004 Betaine Anhydrous
Drug:NITI-005 Nitisinone
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Quarterly Financial Results Conference Call
Full Press ReleaseSEC FilingsOur ETON Tweets

About Gravity Analytica

Recent News

  • 01.03.2025 - Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
  • 12.20.2024 - Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
  • 12.17.2024 - Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial

Recent Filings

  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.03.2025 - EX-99.1 EX-99.1
  • 01.03.2025 - 8-K Current report

DEER PARK, Ill.,Nov. 06, 2024(GLOBE NEWSWIRE) --Eton Pharmaceuticals, Inc.(“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results onTuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at4:30 p.m. ET(3:30 p.m. CT).

Dial in (Audio Only)Toll-free: 888-596-4144
Non-toll free: 646-968-2525
Access Code: 1144771
Webcast:Click Here

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to:investorrelations@etonpharma.com.

The live webcast can also be accessed on the Investors section of Eton’s website athttps://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

AboutEton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website atwww.etonpharma.com.

Investor Relations:

Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:lwilson@insitecony.com

Source:Eton Pharmaceuticals, Inc.

Primary Logo

Source: Eton Pharmaceuticals

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com